

.jpg)
As an OB-GYN, I hear the same thing from women every week. They’ve invested time and money in supplements, skincare, and wellness routines. What they want is for that effort to show up in how they look and feel, with steady energy, a clear head, and confidence that they’re aging well.
In a recent survey commissioned by Hers of more than 2,000 U.S. adults, including 1,000 women, at least 1 in 3 of the women respondents in every age group said they’re lacking energy, and at least 1 in 3 said they’re lacking sleep. When even the best routines leave women feeling like they’re on empty, it’s natural they look for something to build on the work they’re already doing. As a result, many women are curious about peptides.
Peptides have gone from trending topics on social media, to one of the most popular conversations I have with women in the exam room. Unfortunately, there’s a significant knowledge and trust gap, and our recent survey shows where women are getting their information. Among adult respondents who’ve heard of peptides, more learned about them from TikTok or social media influencers (25%) than from their doctor (20%).¹ Too often, that leaves women spending more time and money on unregulated sellers and over-the-counter products.
As Chief Medical Officer of Hers, my job is to help women make informed decisions about their health. They deserve clarity on how a treatment works, what the research shows, and what we’re still learning – all under the guidance of an experienced clinician.
That’s why we’re launching Peptides+, a clinically guided specialty designed to support health at the cellular level. Peptides+ connects eligible women with independent, licensed providers who can prescribe individualized care plans anchored in their health history and goals, starting with five foundational treatments that target the body from the inside out.
{inline-gallery}
Peptides are short chains of amino acids that cells use to send signals to one another. Peptides+ includes peptides with other well-known compounds the body relies on. The compounded treatments in Peptides+ contain the below active ingredients:
The journey begins with an intake on a woman’s health history, current medications and goals. An independent, licensed provider trained in peptide therapies then determines whether she’s eligible and which treatment and dosage, if any, makes sense for her. Treatments are compounded in the U.S. and dispensed by U.S. licensed pharmacies.
Peptides+ is available with Care+, which pairs treatment with comprehensive insights and support experience. Customers receive an at-home lab kit and access to lab testing twice a year to track their progress, unlimited support and ongoing check-ins from a dedicated Care Team, and the option to message providers trained in peptide therapy 24/7 with any questions. To give customers and their providers a baseline from day one, without an office visit, Care+ gives women access to the Hers Women’s Panel, an at-home kit for lab testing. It is the first time Hers is offering at-home blood collection for women, providing insights across 22 biomarkers including, hormones, vitamins, heart health and more.
Women have spent years doing the work and finding their own answers. Peptides+ is designed to support that journey, with a clinical team that stays involved, provides clear information on what each treatment does, and develops a plan that moves with them through every stage of life and can change as often as she does.
1Based on an online survey of 2,009 U.S. adults ages 18 and older, including 1,007 women and 1,002 men, commissioned by Hims & Hers and conducted in October 2026. Respondents were 50% women (n=1,007) and 50% men (n=1,002). By age: 18–30, 22% (n=439); 31–45, 26% (n=514); 46–59, 23% (n=466); 60+, 29% (n=590). Participation was voluntary. Some figures reflect subgroups of respondents. Results may not be representative of all Americans.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “over time,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the launch and availability of Peptides+, including the treatments available at launch and their potential benefits; the availability and expected benefits of Care+ and related lab testing and support offerings; and the potential effects of Peptides+ on our customers and our business. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the rollout of Peptides+, and the related customer response; the supply chain for the Peptides+ offering; the evolving clinical evidence and regulatory status of the peptide therapies we offer, and our ability to offer such therapies consistent with regulatory standards; other changes in the application, interpretation, and enforcement of healthcare, pharmacy, compounding, consumer protection, or privacy laws or regulations applicable to our business in the United States; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of November 18, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.